{
  "model": "gemini-3-pro-preview",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 2,
  "workspacePath": "workspaces/gemini-3-pro-preview-tumor-vaccine-ici-run-2",
  "success": false,
  "schemaPass": false,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 228366,
  "agentCostUsd": 0.1320502,
  "graderCostUsd": 0,
  "totalCostUsd": 0.1320502,
  "agentUsage": {
    "promptTokens": 50219,
    "cachedTokens": 20611,
    "responseTokens": 2876,
    "thinkingTokens": 2850,
    "totalTokens": 55945
  },
  "graderUsage": {
    "promptTokens": 0,
    "cachedTokens": 0,
    "responseTokens": 0,
    "thinkingTokens": 0,
    "totalTokens": 0
  },
  "totalUsage": {
    "promptTokens": 50219,
    "cachedTokens": 20611,
    "responseTokens": 2876,
    "thinkingTokens": 2850,
    "totalTokens": 55945
  },
  "modelVersions": [
    "gemini-3-pro-preview"
  ],
  "agentFinalText": "Study overview JSON: output/study_overview.json\nQuantitative findings JSON: output/quantitative_findings.json\nClaim audit JSON: output/claim_audit.json\nPublic summary JSON: output/public_summary.json",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Tumor-bearing mice pooled across repeat experiments receiving combination therapy.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Tumor-bearing mice pooled across matched controls (vaccine only, ICI only, and vehicle).\"\n    },\n    {\n      \"id\": \"human-retro\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment.\"\n    },\n    {\n      \"id\": \"human-vac\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subgroup of patients who received prior SARS-CoV-2 mRNA vaccination.\"\n    },\n    {\n      \"id\": \"human-unvac\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subgroup of patients who had not received SARS-CoV-2 mRNA vaccination.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\"\n  ]\n}\n"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": false,
      "errors": [
        "Quote in C03 was not found verbatim in report: \"Combined intervention ... aligns with better outcomes in the retrospective human cohort.\""
      ],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination improves tumor sensitivity to anti-PD-L1 therapy.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The mechanism involves induction of Type I interferon signaling and improved antigen presentation.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Retrospective human data suggests prior mRNA vaccination correlates with better ICI outcomes.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Combined intervention ... aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Lipid nanoparticles alone are insufficient to cause the sensitization; mRNA is required.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n          \"line_ref\": \"L38\"\n        },\n        {\n          \"quote\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n          \"line_ref\": \"L36\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    }\n  ]\n}\n"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": false,
      "groundingValid": false,
      "errors": [
        "plain_language_summary: Too big: expected string to have <=1200 characters"
      ],
      "content": "{\n  \"headline\": \"COVID-19 mRNA Vaccines May Make Tumors More Vulnerable to Immunotherapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors are powerful cancer drugs that unleash the immune system to fight tumors, but they don't work for everyone. A new study published in Nature suggests that the technology used in COVID-19 mRNA vaccines might help overcome this limitation. Researchers found that injecting mRNA vaccines directly into tumors in mice triggered a strong inflammatory response, specifically a 'Type I interferon' signal. This signal acted like a flare, making the cancer cells more visible to the immune system by increasing the variety of proteins shown on their surface. When combined with standard immunotherapy (anti-PD-L1), the vaccine treatment significantly improved tumor control compared to immunotherapy alone. The study also looked back at records of 130 human patients with metastatic cancer treated with immunotherapy. Those who had previously received a SARS-CoV-2 mRNA vaccine showed better survival rates than those who hadn't. While these results are promising, the human data is preliminary and comes from looking at past records rather than a controlled trial. The findings point to a potential new way to prime 'cold' tumors to respond to treatment, but more research is needed to prove it works safely and effectively in patients.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination induces Type I interferon to prime tumors for immunotherapy.\",\n    \"The treatment expands the range of tumor antigens presented to the immune system.\",\n    \"Retrospective data links prior mRNA vaccination to better immunotherapy outcomes in humans.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study was retrospective and non-randomized, meaning other factors could explain the results.\",\n    \"Animal model results do not always perfectly predict how the treatment will work in humans.\",\n    \"The timing of vaccination and the types of tumors treated varied significantly among patients.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune Checkpoint Inhibitor (ICI)\",\n      \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by blocking proteins that stop immune responses.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Administration of a drug or vaccine directly into a tumor mass.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of protein fragments (peptides) presented on the surface of cells that the immune system scans to detect infection or cancer.\"\n    },\n    {\n      \"term\": \"Type I Interferon\",\n      \"definition\": \"A group of signaling proteins released by cells in response to viruses that heighten the immune system's antiviral defenses.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on cells that prevents the immune system from attacking them; blocking it is a common strategy in cancer immunotherapy.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will these results hold up in a prospective, randomized clinical trial?\",\n    \"What is the optimal timing for administering the mRNA vaccine relative to immunotherapy?\",\n    \"Can this approach work for all tumor types, or only specific ones?\"\n  ]\n}\n"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 22,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-13T17:42:38.070Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-13T17:43:00.266Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-13T17:43:21.637Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-13T17:43:37.606Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-13T17:43:45.842Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-13T17:44:16.445Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-13T17:44:20.725Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-13T17:44:56.359Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-13T17:45:15.302Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T17:45:26.213Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T17:45:47.899Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "error": "LLM JSON call failed after 2 attempt(s)"
  }
}
